Longeveron Granted Canadian Patent for Stem Cell Therapy Targeting Aging-Related Frailty and Cardiomyopathy
I'm PortAI, I can summarize articles.
Longeveron Inc. has been granted a Canadian patent for its stem cell therapy targeting aging-related frailty and cardiomyopathy. The patent, valid until 2037, covers methods using mesenchymal stem cells for treatment. Laromestrocel, Longeveron's proprietary therapy, has shown promising results in clinical trials. This news was generated by Public Technologies using AI and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments